1887

Abstract

A mAb against the NadA protein from strain 3006 (serosubtype B : 2b : P1.2 : P5.2,8) demonstrated strong bactericidal activity against Brazilian epidemic serogroup B strain N44/89 (B : 4,7 : P1.19,15 : P5.5,7) and a serogroup C strain, IMC 2135 (C : 2a : P1.5,2), but not against another serogroup C strain, N1002/90 (C : 2b : P1.3 : P5.8). The immunogenicity of native NadA in an outer-membrane vesicle (OMV) preparation was also tested. Serum from mice immunized with OMV from serogroup B strain N44/89, which contains the NadA protein, showed bactericidal activity against serogroup B and C strains possessing NadA. In dot-blot analysis of 100 serogroup B and 100 serogroup C isolates from Brazilian patients, the mAb to NadA recognized about 60 % of the samples from both serogroups. The molecular mass of the NadA protein from strain N44/89 determined by mass spectrometry was 37 971 Da and the peptide sequences were identical to those of NadA from strain MC58.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.05017-0
2003-02-01
2020-05-27
Loading full text...

Full text loading...

/deliver/fulltext/jmm/52/2/121.html?itemId=/content/journal/jmm/10.1099/jmm.0.05017-0&mimeType=html&fmt=ahah

References

  1. Anderson E. L, Bowers T, Mink C. M, Kennedy D. J, Belshe R. B, Harakeh H, Pais L, Holder P, Carlone G. M. 1994; Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 62:3391–3395
    [Google Scholar]
  2. Blake M. S, Gotschlich E. C. 1986; Functional and immunological properties of pathogenic Neisseria surface proteins. In Bacterial Outer Membranes as Model Systems pp 377–400 Edited by Inoue M. New York: Wiley;
    [Google Scholar]
  3. Boslego J, Garcia J, Cruz C. 11 other authors 1995; Efficacy, safety, and immunogenicity of a meningococcal group B (15 : P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine 13:821–829 [CrossRef]
    [Google Scholar]
  4. Comanducci M, Bambini S, Brunelli B. 12 other authors 2002; NadA, a novel vaccine candidate of Neisseria meningitidis . J Exp Med 195:1445–1454 [CrossRef]
    [Google Scholar]
  5. Frasch C. E. 1995; Meningococcal vaccines. In Meningococcal Disease pp 245–283 Edited by Cartwright K. New York: Wiley;
    [Google Scholar]
  6. Frasch C. E, Robbins J. D. 1978; Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model. J Exp Med 147:629–644 [CrossRef]
    [Google Scholar]
  7. Frasch C. E, Zollinger W. D, Poolman J. T. 1985; Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes. Rev Infect Dis 7:504–510 [CrossRef]
    [Google Scholar]
  8. Fukasawa L. O, Gorla M. C. O, Schenkman R. P. F, Garcia L. R, Carneiro S. M, Raw I, Tanizaki M. M. 1999; Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine 17:2951–2958 [CrossRef]
    [Google Scholar]
  9. Fukasawa L. O, Gorla M. C. O, Lemos A. P, Brandileone M. C, Schenkman R. P. F, Frasch C. E, Raw I, Tanizaki M. M. 2000; A 190 kDa conserved surface protein from Neisseria meningitidis that induces bactericidal antibodies. In Abstract Book of the Twelfth International Pathogenic Neisseria Conference Galveston, TX, USA:
    [Google Scholar]
  10. Granoff D. M, Gupta R. K, Belshe R. B, Anderson E. L. 1998; Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 178:870–874 [CrossRef]
    [Google Scholar]
  11. Kearney J. F, Radbruch A, Liesegang B, Rajewsky K. 1979; A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123:1548–1550
    [Google Scholar]
  12. Martin D, Cadieux N, Hamel J, Brodeur B. R. 1997; Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med 185:1173–1183 [CrossRef]
    [Google Scholar]
  13. Maslanka S. E, Gheesling L. L, Libutti D. E. 14 other authors 1997; Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 4:156–167
    [Google Scholar]
  14. Milagres L. G, Ramos S. R, Sacchi C. T, Melles C. E, Vieira V. S, Sato H, Brito G. S, Moraes J. C, Frasch C. E. 1994; Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun 62:4419–4424
    [Google Scholar]
  15. Pizza M, Scarlato V, Masignani V. 33 other authors 2000; Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287:1816–1820 [CrossRef]
    [Google Scholar]
  16. Poolman J. T. 1995; Development of a meningococcal vaccine. Infect Agents Dis 4:13–28
    [Google Scholar]
  17. Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, Hill J, Barker M, Miller E. 2000; Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 181:761–764 [CrossRef]
    [Google Scholar]
  18. Rosenqvist E, Hoiby E. A, Wedege E, Kusecek E, Achtman M. 1993; The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis 167:1065–1073 [CrossRef]
    [Google Scholar]
  19. Sacchi C. T, Lemos A. P, Popovic T. 8 other authors 2001; Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997–1998: overview and implications for vaccine development. J Clin Microbiol 39:2897–2903 [CrossRef]
    [Google Scholar]
  20. Shevchenko A, Chernushevic I, Shevchenko A, Wilm M, Mann M. 2002; ‘De novo’ sequencing of peptides recovered from in-gel digested protein by nanoelectrospray tandem mass spectrometry. Mol Biotechnol 20:107–118 [CrossRef]
    [Google Scholar]
  21. Twumasi P. A Jr, Kumah S, Leach A. 9 other authors 1995; A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 171:632–638 [CrossRef]
    [Google Scholar]
  22. Wedege E, Froholm L. O. 1986; Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 51:571–578
    [Google Scholar]
  23. Wedege E, Hoiby E. A, Rosenqvist E, Froholm L. O. 1990; Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol 31:195–201 [CrossRef]
    [Google Scholar]
  24. Zollinger W. D. 1997; New and improved vaccines against meningococcal disease. In New Generation Vaccines . pp 469–488 Edited by Levine M. M., Woodrow G. C., Kaper G. S., Cobon J. B. New York: Marcel Dekker;
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.05017-0
Loading
/content/journal/jmm/10.1099/jmm.0.05017-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error